Not applicableLooking for participantsNCT07052565What this trial is testingCAR-T Cells Therapy for Patients With Autoimmune DiseasesWho this might be right forAutoimmune Diseases Anhui Provincial Hospital 18
Early research (Phase 1)Study completedNCT03448393What this trial is testingCD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell MalignanciesWho this might be right forLymphoma, Non-HodgkinLeukemia, Lymphocytic, B CellB-Cell Lymphoma+7 more National Cancer Institute (NCI) 54
Testing effectiveness (Phase 2)Study completedNCT04325841What this trial is testingPhase II Study of Anti-CD19 CAR-T Cells Treating Leukemia ChildrenWho this might be right forAcute Lymphoblastic Leukemia, PediatricAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia Beijing Boren Hospital 2
Early research (Phase 1)Looking for participantsNCT06408194What this trial is testingAutologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell MalignanciesWho this might be right forLeukemiaAcute Lymphoblastic Leukemia Stanford University 28
Very early researchNot Yet RecruitingNCT07596680What this trial is testingCD19/BCMA-Targeted Universal CAR-T Cell Injection for the Treatment of Autoimmune DiseasesWho this might be right forSLE - Systemic Lupus ErythematosusSystemic SclerosisANCA Associated Vasculitis+2 more Nanjing Bioheng Biotech Co., Ltd. 30
Testing effectiveness (Phase 2)Looking for participantsNCT06479356What this trial is testingCD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell LymphomaWho this might be right forNon-Hodgkin LymphomaLarge B-cell Lymphoma Shanghai Ming Ju Biotechnology Co., Ltd. 12
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06435897What this trial is testingAutoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T CellsWho this might be right forAutoimmune Diseases Shenzhen Geno-Immune Medical Institute 30
Testing effectiveness (Phase 2)Looking for participantsNCT06359041What this trial is testingRESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia GravisWho this might be right forGeneralized Myasthenia Gravis (gMG) Cabaletta Bio 24
Early research (Phase 1)Looking for participantsNCT07073547What this trial is testingA Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)Who this might be right forMultiple Myeloma AstraZeneca 40
Early research (Phase 1)Looking for participantsNCT07304154What this trial is testingA Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic DiseasesWho this might be right forChronic Inflammatory Demyelinating PolyneuropathyMyasthenia GravisMultiple Sclerosis Kite, A Gilead Company 52
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07613788What this trial is testingRimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCLWho this might be right forRelapsed/Refractory Large B-cell Lymphoma (LBCL) Ruijin Hospital 100
Testing effectiveness (Phase 2)Looking for participantsNCT06104592What this trial is testingSingle-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCLWho this might be right forLarge B-cell LymphomaRelapsed Non-Hodgkin Lymphoma H. Lee Moffitt Cancer Center and Research Institute 27
Not applicableLooking for participantsNCT05618041What this trial is testingThe Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological MalignanciesWho this might be right forAcute Lymphoblastic LeukemiaLymphomaMultiple Myeloma Hebei Senlang Biotechnology Inc., Ltd. 50
Early research (Phase 1)Active Not RecruitingNCT04007029What this trial is testingModified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic LeukemiaWho this might be right forCD19 PositiveCD20 PositiveRecurrent Chronic Lymphocytic Leukemia+11 more Jonsson Comprehensive Cancer Center 24
Very early researchUnknownNCT04303247What this trial is testingCD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHLWho this might be right forB-cell Lymphoma RefractoryB-cell Lymphoma Recurrent Xinqiao Hospital of Chongqing 30
Not applicableLooking for participantsNCT04107285What this trial is testingLooking at Cognitive and Brain Changes in People With Lymphoma Receiving CAR-T TherapyWho this might be right forLymphoma Receiving CAR-T Therapy Memorial Sloan Kettering Cancer Center 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT07094477What this trial is testingStudy of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell LymphomaWho this might be right forLymphoma Daihong Liu 50
Large-scale testing (Phase 3)Looking for participantsNCT07391657What this trial is testingA Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)Who this might be right forRelapsed Refractory Multiple Myeloma AstraZeneca 508
Early research (Phase 1)UnknownNCT04516551What this trial is testingAnti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCTWho this might be right forRelapsed Adult ALLB Cell Leukemia Xinqiao Hospital of Chongqing 18
Early research (Phase 1)Looking for participantsNCT02443831What this trial is testingCARPALL: Immunotherapy With CD19+CD22 CAR T-cells for CD19+ and CD22+ Acute Lymphoblastic LeukaemiaWho this might be right forAcute Lymphoblastic Leukemia University College, London 50